Statewide longitudinal survey of psychotropic medication use for persons with mental retardation: 1994 to 2000

American Journal on Mental Retardation

Volumn 109, Issue 4, 2004, Pages 322-331

  Spreat, Scott ^a   Conroy, James W ^b   Fullerton, Amanda ^b  

^a Woods Services   (United States)

^b Center for Outcome Analysis   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE; PSYCHOTROPIC AGENT; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; VALPROATE SEMISODIUM;

DATA COLLECTION METHOD; DRUG USE; HEALTH SERVICE; HEALTH SURVEY; HUMAN; INSTITUTIONAL CARE; MEDICAL LITERATURE; MENTAL DEFICIENCY; PREVALENCE; PSYCHIATRY; PUBLIC HEALTH; QUESTIONNAIRE; REVIEW; UNITED STATES; ADULT; ARTICLE; DRUG UTILIZATION; FEMALE; LONGITUDINAL STUDY; MALE; STATISTICS;

ADULT; DRUG UTILIZATION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MENTAL RETARDATION; OKLAHOMA; PSYCHOTROPIC DRUGS; QUESTIONNAIRES;

EID: 5444222182     PISSN: 08958017     EISSN: None     Source Type: Journal    
DOI: 10.1352/0895-8017(2004)109<322:SLSOPM>2.0.CO;2     Document Type: Review

References (13)

1. Aman, M., & Singh, N. (1988). Patterns of drug use, methodological considerations, measurement techniques, and future trends. In M. G. Aman & N. N. Singh (Eds.), Psychopharmacology of the developmental disabilities (pp. 1-28). New York: Springer-Verlag.
2. Conroy, J. (1996). Patterns of community placement II: The first 27 months of the Coffelt settlement. Ardmore, PA: Center for Outcome Analysis.
3. Fahs, J. (1996). Habilitative neuropsychiatry: Psychopharmacology. Kingston, NY: National Association for the Dually Diagnosed.
4. Harrington, C., Razmic, G., Gemmen, E., Hughes, C., Golden, K., Roginson, G., & Scallet, L. (2000). Access and utilization of new antidepressant and antipsychotic medications. Fairfax, VA: Lewin Group.
5. Hill, B., Balow, E., & Bruininks, R. (1985). A national study of prescribed drugs in institutions and community residential facilities for mentally retarded people. Psychopharmacology Bulletin, 21, 279-284.
6. Intagliata, J., & Rinck, C. (1985). Psychoactive drug use in public and community residential facilities for mentally retarded persons. Psychopharmacology Bulletin, 21, 279-284.
7. Lipman, R. (1970). The use of psychopharmacological agents in residential facilities for the retarded. In F. Menolascino (Ed.), Psychiatric approaches to mental retardation (pp. 387-398). New York: Basic Books.
8. Oklahoma State University. (1992). Developmental Disabilities Quality Assurance Questionnaire. Stillwater: Oklahoma State University.
9. Reber, M. (2002). Dual diagnosis: Mental retardation and psychiatric disorders. In M. Batshaw (Ed.), Children with disabilities (5th ed., pp. 347-363). Baltimore: Brookes.
10. Spreat, S., & Behar, D. (1994). Trends in the residential (inpatient) treatment of individuals with a dual diagnosis. Journal of Consulting and Clinical Psychology, 62, 43-48.
11. Spreat, S., Conroy, J., & Jones, J. (1997). Use of psychotropic medication in Oklahoma: A statewide survey. American Journal on Mental Retardation, 102, 80-85.
12. Thinn, K., Clarke, D. J., & Corbett, J. A. (1990). Psychotropic drugs and mental retardation: II. A comparison of psychoactive drug use before and after discharge from hospital to community. Journal of Mental Deficiency Research, 34, 397-407.
13. Weisblatt, S. (1996). Mental health assessment and treatment for persons with developmental disabilities. Training session offered by the Pennsylvania Department of Public Welfare Office of Mental Retardation, Harrisburg.